Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Income (2016 - 2025)

Historic Net Income for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $846000.0.

  • Anika Therapeutics' Net Income rose 10301.36% to $846000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 5650.33%. This contributed to the annual value of -$47.6 million for FY2024, which is 3997.45% up from last year.
  • Anika Therapeutics' Net Income amounted to $846000.0 in Q3 2025, which was up 10301.36% from $677000.0 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Net Income high stood at $16.2 million for Q4 2023, and its period low was -$28.1 million during Q3 2024.
  • Moreover, its 5-year median value for Net Income was -$2.6 million (2024), whereas its average is -$2.3 million.
  • Examining YoY changes over the last 5 years, Anika Therapeutics' Net Income showed a top increase of 41137.91% in 2022 and a maximum decrease of 85398.55% in 2022.
  • Anika Therapeutics' Net Income (Quarter) stood at -$3.2 million in 2021, then soared by 411.38% to $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then crashed by 219.74% to -$19.4 million in 2024, then soared by 104.37% to $846000.0 in 2025.
  • Its last three reported values are $846000.0 in Q3 2025, $677000.0 for Q2 2025, and -$915000.0 during Q1 2025.